Atrial natriuretic peptide and fludrocortisone therapy in congenital adrenal hyperplasia.
Arisaka
O
O
Department of Paediatrics, Juntendo University School of Medicine, Tokyo, Japan.
Hosaka
A
A
Arisaka
M
M
Shimura
N
N
Nakayama
Y
Y
Yamashiro
Y
Y
Yabuta
K
K
D019326:17-alpha-Hydroxyprogesterone; D000284:Administration, Oral; D000312:Adrenal Hyperplasia, Congenital / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D000367:Age Factors; D009320:Atrial Natriuretic Factor / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005438:Fludrocortisone / Q000008:administration & dosage*; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage*; D006908:Hydroxyprogesterones / Q000097:blood; D007223:Infant; D012083:Renin / Q000097:blood; D012964:Sodium / Q000378:metabolism; D014882:Water-Electrolyte Balance / Q000187:drug effects / Q000502:physiology
D006908:Hydroxyprogesterones; D019326:17-alpha-Hydroxyprogesterone; D009320:Atrial Natriuretic Factor; D012964:Sodium; D012083:Renin; D005438:Fludrocortisone; D006854:Hydrocortisone